Pr Yohann Loriot
- Spécialité
- Oncologue médical, expert urologie
- Titre
- Chef adjoint du département des Essais Précoces (DITEP)
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- Plain language summary of the THOR Cohort 1 study comparing treatment with erdafitinib or chemotherapy in advanced or metastatic urothelial cancer. (1 juil. 2025)
- Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer. (7 juin 2025)
- Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. (3 juin 2025)
- Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. (1 juin 2025)
- Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study. (14 mai 2025)